Media coverage about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trillium Therapeutics earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.5271547730262 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

TRIL has been the topic of a number of research analyst reports. HC Wainwright set a $7.00 target price on shares of Trillium Therapeutics and gave the company a “buy” rating in a report on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a report on Wednesday, July 5th. Finally, Zacks Investment Research raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $15.00.

Shares of Trillium Therapeutics (NASDAQ:TRIL) traded up 2.27% during midday trading on Thursday, hitting $6.75. 121,055 shares of the stock were exchanged. The stock’s market capitalization is $72.86 million. The firm’s 50 day moving average is $5.23 and its 200-day moving average is $5.17. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $15.51.

WARNING: “Trillium Therapeutics (TRIL) Earns Daily News Sentiment Score of 0.19” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Insider Buying and Selling by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.